Skip to main content
. 2022 Jan 7;26(1):117–127. doi: 10.1007/s40291-021-00573-z

Fig. 2.

Fig. 2

The design of antisense oligonucleotides (ASOs) in this study. The 14-mer gapmer ASO targeting human glucocorticoid receptor (GR) RNA, named gap-GR14 in this study, was selected as a lead sequence. Three 18-mer gapmer ASOs (gap-GR18-1, gap-GR18-2, and gap-GR18-3) were designed based on gap-GR14 sequence by extending the oligonucleotides on the 5′-sides, 3′-sides, and both sides. Gap DNA and LNA are indicated in lowercase and uppercase bold, respectively. All oligonucleotides were fully modified with phosphorothioate linkages. Lead sequences are shown in light orange, extended sequences in light blue, and phosphorothioate is indicated by a “^” symbol